CN101176757B - Pomegranate leaf extract preparations - Google Patents
Pomegranate leaf extract preparations Download PDFInfo
- Publication number
- CN101176757B CN101176757B CN2007101233649A CN200710123364A CN101176757B CN 101176757 B CN101176757 B CN 101176757B CN 2007101233649 A CN2007101233649 A CN 2007101233649A CN 200710123364 A CN200710123364 A CN 200710123364A CN 101176757 B CN101176757 B CN 101176757B
- Authority
- CN
- China
- Prior art keywords
- extract
- volatile oil
- quercetin
- filtrate
- filtration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a guava leaf extract composite preparation, which is characterized in that volatile oil is extracted from the guava leaf, and the extracts is compounded to be the preparation after water extraction. The invention can be granule, powder, oral liquid and capsule, which is used to treat infantile diarrheas and diabetes.
Description
Technical field
The invention belongs to the Chinese medicine preparation preparing technical field, particularly the preparation of pomegranate leaf extract preparations.
Background technology
Folium Psidii Guajavae claims chicken to vow tea, kind Folium Persicae etc. again, is the leaf of myrtle Fructus psidii guajavae immaturus Psidium guajava L., among the people the commonly using in diarrhea treatment in Guangdong and Guangxi Provinces." Guangxi Chinese medicinal herbal " note has: " sweet-puckery flavor, property is flat, and is nontoxic " " spleen invigorating astringing intestine to stop diarrhea.Control dysentery, diarrhoea ", " Nanning City's medicine will " note " astringing to arrest diarrhea.Control and have loose bowels, chronic dysentery, eczema, wound hemorrhage ", " south of the Five Ridges herbal ", " Guangxi Chinese herbal medicine handbook commonly used among the people, " national Chinese herbal medicine compilation ", " Fujian medicine will ", " choosing of Yunnan Chinese herbal medicine " etc. are all put down in writing these product and be can be used for treatment diarrhoea.This project inventor's hour diarrhoea is with Folium Psidii Guajavae for oral administration curing to boil water.Modern pharmacological research and clinical report pomegranate leaf have therapeutical effect to diabetes.
The present invention has announced that contains a pomegranate leaf extract preparations, said preparation can effectively keep being used for the treatment of in the pomegranate leaf effective ingredient and the proportioning thereof of infantile diarrhea and diabetes, and this group extract can easily be prepared into granule, powder, oral liquid and soft capsule.
Summary of the invention
Purpose of the present invention provide a kind of can active constituent content and proportioning can with consistent, the easy to use again pomegranate leaf extract preparations of primary pomegranate leaf decoct.
The present invention is implemented by following scheme:
A. exsiccant pomegranate leaf is added 6-10 times of water logging and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 6-8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A;
D. merge a, b gained volatile oil is extract B.
E. extract A can get extract C behind further precipitate with ethanol purification.
F. be prepared into conventional preparation technology and contain extract A and B or contain extract B and the granule of C, powder, oral liquid and suspensoid.
In the above-mentioned implementation process, its quality control is the extract A of gained, it is characterized by every gram extract A and contains Quercetin 0.008-0.02 gram.Extract B, the content of its feature australene in extract B are that 18-22%, D-limonene content are that 10-14%, caryophyllene content are 14-18%.Preparation is counted the 0.02-0.04 gram with contained said extracted thing with Quercetin in each dose.
Pomegranate leaf clinical practice among the people no matter be used for the treatment of infantile diarrhea or diabetes all with the usefulness that is decocted in water for oral dose, and the used extract of the pharmacological evaluation of reported in literature all with organic solvent extraction to improve the content of some composition, although made effect in the experimental model, on the safety that dosage uses, lack effective confirmation clinically.And the contained pomegranate leaf extract of this preparation can be consistent with primary pomegranate leaf decoct at active constituent content and proportioning, fixed the standard of quality control simultaneously for preparation, guaranteed that quality of the pharmaceutical preparations safety is controlled, and is easy to use.
Description of drawings
Accompanying drawing is the assay makings collection of illustrative plates example of extract B.
Instrument model: U.S. TRACE GC-MS
One. the mass spectrum condition:
Ion source: EI source
Electron energy: 70ev
Sweep limits: 35-625amu
Ion source temperature: 200 ℃
Two. gas phase condition:
Carrier gas: high-purity helium
Chromatographic column: CP-SIL 8CB-MS (30m * 0.25mmm * 0.25um)
Gasification temperature: 250 ℃
Column temperature: be raised to 100 ℃ with 5 ℃/min from 50 ℃ (6min), again with 3 ℃/min to 190 ℃ (5min)
Split ratio: 1: 40
Carrier gas flux: 1.0ml/min
Sample size: 0.2ul
Spectrum storehouse: NIST spectrum storehouse
The specific embodiment
The present invention is further illustrated below in conjunction with specific embodiment.
Embodiment 1
A. exsiccant pomegranate leaf is added 10 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 10mg in every gram extract A;
D. merge a, b gained volatile oil is extract B.
E. be prepared into the granule that contains extract A and B with conventional preparation technology.
F. the usage of granule is each 1 bag, and three times on the one, every bag of active constituent content is no less than 20mg. in Quercetin
The mensuration of Quercetin:
1 instrument and reagent
Day island proper Tianjin high performance liquid chromatograph, the CLASS-VP5.032 chromatographic work station;
The Quercetin reference substance provides (lot number 100081-200406) by Nat'l Pharmaceutical ﹠ Biological Products Control Institute;
Water is distilled water; Methanol is chromatographically pure; Hydrochloric acid is analytical pure.
2 methods and result
2.1 chromatographic condition
Chromatographic column: Dikma C18 (250mm * 4.6mm * 5 μ m);
Mobile phase: methanol-0.4% phosphoric acid solution (55: 45);
Detect wavelength: 372nm; Flow velocity: 1.0mL/min: column temperature: 30 ℃; Sample size: 10 μ L.
2.2 sample determination
2.2.1 the preparation precision of reference substance solution takes by weighing the Quercetin reference substance and makes the solution of 0.1mg/mL with dissolve with methanol, shakes up.The accurate 10 μ L sample introductions of drawing inject high performance liquid chromatograph.
Get preparation grind into powder to be measured, accurate claim surely, accurate methanol one hydrochloric acid (19: the 1) 50mL that adds puts reflux 30min in the water-bath, puts coldly, filters, and injects high performance liquid chromatograph.Measure total quercetin content.
Embodiment 2
A. exsiccant pomegranate leaf is added 10 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 10mg in every gram extract A;
D. merge a, b gained volatile oil is extract B.
E. be prepared into the powder that contains extract A and B with conventional preparation technology.
F. the usage of powder is each one bag, and three times on the one, every bag of active constituent content is no less than 20mg in Quercetin, is no more than 40mg.
The assay method of Quercetin is with reference to embodiment 1.
Embodiment 3
A. exsiccant pomegranate leaf is added 8 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 6 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 8mg in every gram extract A;
D. merge a, b gained volatile oil is extract B.
E. be prepared into the oral liquid that contains extract A and B with conventional preparation technology.
F. the usage of oral liquid is each one, and three times on the one, every active constituent content is no less than 20mg in Quercetin, is no more than 40mg.
The assay method of Quercetin is with reference to embodiment 1.
Embodiment 4
A. exsiccant pomegranate leaf is added 10 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 10mg in every gram extract A;
D. merge a, b gained volatile oil is extract B.
E. extract A is through further getting extract C behind the precipitate with ethanol purification.
F. be prepared into the granule that contains extract B and C with conventional preparation technology.
G. the usage of granule is each one bag, and three times on the one, every bag of active constituent content is no less than 20mg in Quercetin, is no more than 40mg.
The assay method of Quercetin is with reference to embodiment 1.
A. exsiccant pomegranate leaf is added 10 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 10mg in every gram extract A;
D. merge a, b gained volatile oil is extract B.
E. extract A is through further getting extract C behind the precipitate with ethanol purification.
F. be prepared into the soft capsule that contains extract B and C with conventional preparation technology.
G. usage is that each consumption active constituent content is no less than 20mg with the Quercetin note, is no more than 40mg.
The assay method of Quercetin is with reference to embodiment 1
Claims (3)
1. be used for the treatment of the Folium Psidii Guajavae extract preparation of infantile diarrhea, it is characterized in that making by following steps:
A. exsiccant Folium Psidii Guajavae is added 10 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 10mg in every gram extract A;
D. merge a, b gained volatile oil is extract B;
E. extract A and B are prepared into granule with conventional preparation technology;
F. every bag of active constituent content of granule is no less than 20mg in Quercetin.
2. be used for the treatment of the Folium Psidii Guajavae extract preparation of infantile diarrhea, it is characterized in that making by following steps:
A. exsiccant Folium Psidii Guajavae is added 10 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 8 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 10mg in every gram extract A;
D. merge a, b gained volatile oil is extract B;
E. extract A and B are prepared into powder with conventional preparation technology;
F. every bag of active constituent content of powder is no less than 20mg in Quercetin, is no more than 40mg.
3. be used for the treatment of the Folium Psidii Guajavae extract preparation of infantile diarrhea, it is characterized in that making by following steps:
A. exsiccant Folium Psidii Guajavae is added 8 times of water loggings and steep reflux, extract, volatile oil after 30 minutes, leave and take filtrate after the filtration;
B. residue adds 6 times of water reflux, extract, volatile oil again, leaves and takes filtrate after the filtration;
C. step a, b gained filtrate are merged, concentrate, getting dry extract after the drying is extract A, quercetin content is no less than 8mg in every gram extract A;
D. merge a, b gained volatile oil is extract B;
E. extract A and B are prepared into oral liquid with conventional preparation technology;
F. every active constituent content of oral liquid is no less than 20mg in Quercetin, is no more than 40mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101233649A CN101176757B (en) | 2007-06-25 | 2007-06-25 | Pomegranate leaf extract preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101233649A CN101176757B (en) | 2007-06-25 | 2007-06-25 | Pomegranate leaf extract preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101176757A CN101176757A (en) | 2008-05-14 |
| CN101176757B true CN101176757B (en) | 2011-11-09 |
Family
ID=39403278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101233649A Expired - Fee Related CN101176757B (en) | 2007-06-25 | 2007-06-25 | Pomegranate leaf extract preparations |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101176757B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210747A (en) * | 2011-06-02 | 2011-10-12 | 深圳清华大学研究院 | Hypoglycemic pharmaceutical preparation and preparation method thereof |
| CN103977078B (en) * | 2014-04-28 | 2015-09-30 | 黎芷杉 | A kind of Chinese medicine preparation and production method thereof for the treatment of people's dysentery |
| CN104127394A (en) * | 2014-07-15 | 2014-11-05 | 沈祥春 | Application of above one of alpha-pinene, beta-pinene, 1,8-eudesmol and camphene in preparation of human blood vessel endothelial cell damage treatment medicines |
| CN104706784A (en) * | 2015-03-25 | 2015-06-17 | 唐肖近 | Traditional Chinese medicine for treating diarrhea |
| CN105232594A (en) * | 2015-11-11 | 2016-01-13 | 王书汉 | Extracting method for effective components of pomegranate leaves and obtained product |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850167A (en) * | 2006-03-07 | 2006-10-25 | 博仲盛景医药技术（北京）有限公司 | Thirsty-relieving blood-sugar-reducing dropping pills and preparing method |
-
2007
- 2007-06-25 CN CN2007101233649A patent/CN101176757B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850167A (en) * | 2006-03-07 | 2006-10-25 | 博仲盛景医药技术（北京）有限公司 | Thirsty-relieving blood-sugar-reducing dropping pills and preparing method |
Non-Patent Citations (4)
| Title |
|---|
| 刘婷等.用链脲霉素诱发大鼠糖尿病筛选有降血糖活性的传统药物，以及对番石榴作用的研究.《国外医学中医中药分册》.1997,第19卷(第1期),第41-42页. * |
| 张文举等.槲皮素止泻机制研究.《第一军医大学学报》.2003,第23卷(第10期),第1029-1031页. * |
| 李吉来等.番石榴叶挥发油成分的GC-MS分析.《中药材》.1999,第22卷(第2期),第78-80页. * |
| 王波等.番石榴的降血糖作用研究.《现代预防医学》.2005,第32卷(第10期),第1293-1294页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101176757A (en) | 2008-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101176757B (en) | Pomegranate leaf extract preparations | |
| CN103823034B (en) | A kind of honeysuckle reference extract and preparation method thereof | |
| CN102854281B (en) | Detection method of sugar-free strong loquat syrup | |
| CN102657823A (en) | Traditional Chinese medicine composition with anticancer effect and preparation method and detection method thereof | |
| Li et al. | Nuciferine and paeoniflorin can be quality markers of Tangzhiqing tablet, a Chinese traditional patent medicine, based on the qualitative, quantitative and dose-exposure-response analysis | |
| CN108752302A (en) | The purposes of 2- (2- phenethyls) chromone compounds in agalloch eaglewood | |
| CN101757099A (en) | Desmodium-capillary artemisia cholecystagogue, preparation method and quality control method thereof | |
| CN102805767B (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN103721148B (en) | A kind of Fructus Alpiniae Oxyphyllae compositions treating acute/chronic gastroenteritis and preparation method thereof | |
| CN101428090A (en) | Tibet picrorhiza rhizome composition with specific spectrum effect relationship | |
| Tao et al. | Establishment of a rapid and sensitive UPLC-MS/MS method for pharmacokinetic determination of nine alkaloids of crude and processed Corydalis turtschaninovii Besser aqueous extracts in rat plasma | |
| CN102058828B (en) | Medicinal composition and detection method for preparation thereof | |
| CN101780126B (en) | Ginsenoside compound in syringa pubescens turca and extraction method and application thereof | |
| CN103301177A (en) | Preparation method and mass control method for mahonia duclouxiana gagnep total alkaloids | |
| CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN102895438B (en) | Application of rhizoma acori graminei extract in preparing drug for treating Alzheimer | |
| CN103127251B (en) | Overground part extract of rheum officinale, extraction and purification method and use thereof | |
| CN102321094B (en) | New Gelsmium elegans Benth. alkaloid compound as well as preparation method and application thereof | |
| CN101642492B (en) | Drug for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN101721434B (en) | Active ingredients of fomes officinalis, preparation method thereof and use thereof | |
| CN102058829B (en) | Medicine composition and detection method of preparations of medicine composition | |
| CN101428077B (en) | Traditional Chinese medicine composition for treating diabetes | |
| Huang et al. | Simultaneous UPLC analysis of three major flavonoids in granule decoctions of Fructus aurantii-type formulae | |
| CN103919885B (en) | A kind of preparation method of soft capsule for nasosinusitis and application | |
| CN103830302A (en) | Preparation method and application of effective component of herba kalimeridis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Tan Biying Document name: Notification of Passing Examination on Formalities |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111109 Termination date: 20180625 |